

RLL-297US

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: KHANNA *et al.*
Serial No.: 10/690,897 Examiner: Patricia L. Morris
Filing Date: 10/22/2003 Group Art Unit: 1625
For: AMORPHOUS FORM OF ESOMEPRAZOLE SALTS

Certificate of Facsimile Transmission

I certify that this correspondence, consisting of one page, is being sent via facsimile transmission to (703) 872-9306 to Technology Group 1625 of the United States Patent and Trademark Office on February 28, 2005


Susan Dolci

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


**RESPONSE TO RESTRICTION REQUIREMENT MAILED
JANUARY 28, 2005**

In response to the Office Action dated January 28, 2005, Applicants elect Group I as defined by Examiner, claims 1-16. Examiner is therefore requested to examine these claims immediately.

Authorization is hereby given to charge any fees deemed to be due in connection with this Response to Deposit Account No. 50-0912.

Respectfully submitted,

KHANNA *et al.*

By: 
William D. Hare
Reg. No. 44,739

Date: February 28, 2005

Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, New Jersey 08540
Tel: (609) 720-5378
Fax: (609) 514-9779